Value Drug Company V. Takeda Pharmaceuticals, U.S.A, Inc., Et al, No. 21-cv03500) (E.D PA.)
Faruqi & Faruqi represents a proposed class of direct purchasers of Takeda Pharmaceuticals' Colcrys, a prescription drug used for the treatment of Familial Mediterranean Fever and for the treatment and prevention of gout flares. The complaint alleges ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
Faruqi & Faruqi, LLP Announces Final Approval of a $2 Million Settlement in Sterrett v. Sonim Technology, Inc.
Faruqi & Faruqi, LLP is pleased to announce that the Court has granted final approval of the settlement in Sterrett v. Sonim Techs., Inc., et al., No. 3:19-cv-06416-MMC (N.D. Cal.), a federal securities class action. Faruqi & Faruqi, LLP serves as Class ...
Katherine M. Lenahan at New York office
Faruqi & Faruqi Reaches Settlement on Behalf of Investors of Revolution Lighting Technologies, Inc.
Faruqi & Faruqi, LLP, Lead Counsel, is pleased to announce that Lead Plaintiff, on behalf of himself and the proposed class, reached a settlement with defendants Revolution Lighting Technologies, Inc. ("Revolution Lighting"), Robert V. LaPenta, Charles ...
James M. Wilson, Jr., Robert W. Killorin at New York office
CV Sciences, Inc.
On November 15, 2018, United States District Judge Jennifer A. Dorsey of the United States District Court for the District of Nevada appointed Faruqi & Faruqi, LLP to serve as Lead Counsel in Smith v. CV Sciences, Inc., et al., No. 2:18-cv-01602. On August ...
James M. Wilson, Jr., Robert W. Killorin at New York office
In re Novartis and Par Antitrust Litig., No. 18-cv-04361 (S.D.N.Y.)
In the Exforge case, Faruqi & Farqui represents a pharmaceutical wholesaler and a proposed class of direct purchasers of the hypertension drug, Exforge. The complaint alleges that Novartis entered into a reverse payment agreement with Par to delay Par's ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Zetia (Ezetimibe) Antitrust Litig., No. 18-md-02836 (E.D. Va.)
In the Zetia case, Faruqi & Faruqi represents a class of direct purchasers of Merck & Co.'s Zetia (ezetimibe), a drug used to treat high cholesterol. The case alleges that Merck entered into an unlawful reverse payment settlement with generic manufacturers ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litig., No. 18-md-2819 (E.D.N.Y.)
In the Restasis case, Faruqi & Faruqi represents a proposed class of direct purchasers of Restasis. The direct purchasers alleged that the drug's manufacturer, Allergan, Inc., delayed entry of a generic version of Restasis by procuring patents by fraud, ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
GoPro, Inc. (GPRO)
Faruqi & Faruqi, LLP Updates GoPro, Inc. (GPRO) Investors Regarding A Federal Securities Class Action Lawsuit On February 6, 2017, Senior District Judge Claudia Wilken of the United States District Court for the Northern District of California appointed ...
James M. Wilson, Jr., Robert W. Killorin at New York office
Smith Drug Co. v. Actavis (Namenda), No. 15-7488 (S.D.N.Y.)
Smith Drug Co. v. Actavis (Namenda), No. 15-7488 (S.D.N.Y.), Faruqi & Faruqi representing a pharmaceutical wholesaler and a proposed class of direct purchasers of Actavis' Namenda XR, alleging that Actavis Actavis engaged in an illegal product hop to ...
Joseph T. Lukens, Peter Kohn at New York office
In re Celebrex Antitrust Litig., No. 14-00361 (E.D. Va.)
In re Celebrex Antitrust Litig., No. 14-00361 (E.D. Va.), Faruqi & Faruqi representing a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer's blockbuster anti-inflammatory drug, Celebrex, alleging that Pfizer procured a patent ...
Joseph T. Lukens, Peter Kohn at New York office
In re Opana Antitrust Litig., No. 14-10150 (N.D. Ill.)
In the Opana case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo Pharmaceuticals' Oxymorphone ER, sold under the brand name Opana ER. The proposed class alleges that Endo and would-be generic ...
Joseph T. Lukens, Peter Kohn at New York office
In re Lidoderm Antitrust Litig., No. 14-2521 (N.D. Cal.)
In the Lidoderm case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo's 5% lidocaine patch, Lidoderm. The case alleges that Endo paid its would-be generic competitor, Watson (now known as Actavis) ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Aggrenox Antitrust Litig., No. 14-2516 (D. Conn.)
In the Aggrenox case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Boehringer Ingelheim's combination stroke prevention drug, Aggrenox. The case alleges that Boehringer paid its would-be generic competitors ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Solodyn Antitrust Litig., No. 14-10438 (D. Mass.)
In the Solodyn case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Medicis's minocycline drug, Solodyn. The case alleges that Medicis engaged in an anticompetitive scheme to prevent lower-priced generic ...
Neill W. Clark, Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Loestrin 24 Fe Antitrust Litig., No. 13-2472 (D.R.I.)
In re Loestrin 24 Fe Antitrust Litig., No. 13-2472 (D.R.I.), Faruqi & Faruqi representing a pharmaceutical wholesaler and a proposed class of direct purchasers of Warner Chilcott's oral contraceptive drug, Loestrin 24 Fe, alleging that Warner Chilcott ...
Neill W. Clark, Joseph T. Lukens, Peter Kohn at Pennsylvania office
In re Nexium (Esomeprazole) Antitrust Litigation, No. 1:12-md-02409-WGY (D. Mass.)
In Nexium, Faruqi & Faruqi, who filed the very first complaint on behalf of direct purchasers, represents a certified class of direct purchasers of the prescription drug Nexium. The direct purchaser class alleges that in the brand manufacturer, AstraZeneca, ...
Joseph T. Lukens, Peter Kohn at Pennsylvania office
Mylan Pharmaceuticals, Inc. v. Warner Chilcott Public Limited Company, et al. No. 12-3824 (E. D. Pa.)
In this case, nicknamed the Doryx case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of Warner-Chilcott's branded drug, Doryx (delayed-release doxycycline hyclate). The case alleges that Warner-Chilcott ...
Neill W. Clark, Peter Kohn at Pennsylvania office
In re Skelaxin (Metaxalone) Antitrust Litigation, No. 12-MD-2343 (E.D. Tenn.)
In this case, nicknamed Skelaxin, Faruqi & Faruqi, LLP represented a pharmaceutical wholesaler and a class of direct purchasers of the muscle relaxant drug Skelaxin (metaxalone), which has been on the market, without generic competition, since the 1960s. ...
Peter Kohn, Joseph T. Lukens at Pennsylvania office
Castro et al. v. Sanofi Pasteur, Inc., No. 11-cv-07178 (D. N. J.)
Faruqi & Faruqi represents a proposed class of pediatricians and pediatric practice groups challenging Sanofi-Pasteur, Inc.'s illegal maintenance of a monopoly on the children's vaccine Menactra in violation of § 2 of the Sherman Act. Plaintiffs allege ...
Peter Kohn, Joseph T. Lukens at Pennsylvania office
Brownson v. Furukawa Electric Co., Ltd. et al, No. 11-14831(E.D. Mich.)
Faruqi & Faruqi represents a proposed class of users of wire harnesses in automobiles against parts manufacturers who pleaded guilty to Department of Justice charges of an conspiracy to fix prices, violating § 1 of the Sherman Act. Defendants are manufacturers ...
Peter Kohn, Joseph T. Lukens at Pennsylvania office